Associate Editor, Journal of Transplanation and Cellular Therapy
Biography
Dr. Robert B. Levy is a Professor in the Department of Microbiology and Immunology and member of the Tumor Biology section of the Sylvester Comprehensive Cancer Center. He obtained his MS/PhD at the Ohio State University and completed his post-doctoral training at the Immunology Branch at the NCI, NIH with Dr. Gene Shearer investigating MHC-restricted T cell antigen recognition and alloreactivity. Dr. Levy has been an independent investigator for >35 years, published >150 manuscripts/chapters on understanding the Immunobiology of hematopoietic stem cell transplantation (HSCT) and a principal investigator on many NIH and foundation grants. He is a reviewer for many Journals and an Associate Editor of the Journal of Transplantation and Cellular Therapy. Dr. Levy was Graduate Program Director for 19 years helping to mentor many students including his own PhD and MD/PhD trainees who have attained positions as Professors at multiple institutions as both elite scientists and educators as well as scientists/research directors in industry. He helped develop and participate in teaching survival skills to graduate students and post-docs at UM for 10 years and is particularly proud of his current and past trainees who were awarded F31, F99/K00, ASCO, tumor biology grant, Batchelor Foundation awards and others.
Education & Training
Education
1975: The Ohio State University, Anatomy
PhD
1974: The Ohio State University, Anatomy
MS
1972: Muhlenberg College, Allentown, PA
BS, Natural Sciences
Post Graduate Training
1983: Immunology Branch, National Cancer Institute
Fellowship
1977: American Cancer Society, Immunology Branch, National Cancer Institute
Post-Doctoral Fellowship
Honors & Awards
No result found
Teaching Interests
Graduate students, Medical Students - Immunobiology Mentoring programs.
Research Interests
My researcy interests focus around translantional work aimed at improving allogeneic hematopoietic stem cell transplants (aHSCT) and anti-tumor immunity. Studies utilize mouse models of HSCT to prevent graft vs host disease and maintain graft vs leukemia responses. We have implemented novel reagents aimed at regulating immune responses including manipulating the Treg cell compartment. Our work has also involved studies examining the role of the STING pathway in aHSCT.
Publications
Disclaimer: The information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, please use this link to inform our data team. Your feedback is greatly appreciated and helps us improve the quality of our content.
